These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 2205097)

  • 1. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III.
    Varade WS; Forristal J; West CD
    Am J Kidney Dis; 1990 Sep; 16(3):196-206. PubMed ID: 2205097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
    West CD; McAdams AJ
    Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum terminal complement component levels in hypocomplementemic glomerulonephritides.
    Clardy CW; Forristal J; Strife CF; West CD
    Clin Immunol Immunopathol; 1989 Mar; 50(3):307-20. PubMed ID: 2917423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis.
    Strife CF; Prada AL; Clardy CW; Jackson E; Forristal J
    J Pediatr; 1990 May; 116(5):S98-102. PubMed ID: 2329415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.
    Clardy CW; Forristal J; Strife CF; West CD
    Clin Immunol Immunopathol; 1989 Mar; 50(3):333-47. PubMed ID: 2917424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant renal histopathologic findings and complement profiles in membranoproliferative glomerulonephritis type III.
    Meyers KE; Strife CF; Witzleben C; Kaplan BS
    Am J Kidney Dis; 1996 Dec; 28(6):804-10. PubMed ID: 8957031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membranoproliferative glomerulonephritis type III: association of glomerular deposits with circulating nephritic factor-stabilized convertase.
    West CD; McAdams AJ
    Am J Kidney Dis; 1998 Jul; 32(1):56-63. PubMed ID: 9669425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between membranoproliferative glomerulonephritis types I and III in clinical presentation, glomerular morphology, and complement perturbation.
    Jackson EC; McAdams AJ; Strife CF; Forristal J; Welch TR; West CD
    Am J Kidney Dis; 1987 Feb; 9(2):115-20. PubMed ID: 3826060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical complement pathway activation in membranoproliferative glomerulonephritis.
    Ooi YM; Vallota EH; West CD
    Kidney Int; 1976 Jan; 9(1):46-53. PubMed ID: 781380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hemolytic method for the measurement of nephritic factor.
    West CD
    J Immunol Methods; 2008 Jun; 335(1-2):1-7. PubMed ID: 18410942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
    Gupta N; Wakefield DN; Clapp WL; Garin EH
    Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paramesangial glomerular deposits in membranoproliferative glomerulonephritis type II correlate with hypocomplementemia.
    West CD; McAdams AJ
    Am J Kidney Dis; 1995 Jun; 25(6):853-61. PubMed ID: 7771481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
    Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
    Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Familial membranoproliferative glomerulonephritis].
    Bogdanović RM; Dimitrjević JZ; Nikolić VN; Ognjanović MV; Rodić BD; Slavković BV
    Srp Arh Celok Lek; 1999; 127(5-6):163-71. PubMed ID: 10500423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complement and nephritic activity in membranoproliferative glomerulonephritis].
    Lévy M; Sich M; Habib R
    Arch Fr Pediatr; 1979 Nov; 36(9 Suppl):LXIV-LXXIV. PubMed ID: 539879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
    Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
    Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.